trimebutine has been researched along with Sepsis in 1 studies
Trimebutine: Proposed spasmolytic with possible local anesthetic action used in gastrointestinal disorders.
Sepsis: Systemic inflammatory response syndrome with a proven or suspected infectious etiology. When sepsis is associated with organ dysfunction distant from the site of infection, it is called severe sepsis. When sepsis is accompanied by HYPOTENSION despite adequate fluid infusion, it is called SEPTIC SHOCK.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ogawa, N | 1 |
| Nakajima, S | 1 |
| Tamada, K | 1 |
| Yokoue, N | 1 |
| Tachibana, H | 1 |
| Okazawa, M | 1 |
| Oyama, T | 1 |
| Abe, H | 1 |
| Yamazaki, H | 1 |
| Yoshimori, A | 1 |
| Sato, A | 1 |
| Kamiya, T | 1 |
| Yokomizo, T | 1 |
| Uchiumi, F | 1 |
| Abe, T | 1 |
| Tanuma, SI | 1 |
1 other study available for trimebutine and Sepsis
| Article | Year |
|---|---|
Trimebutine suppresses Toll-like receptor 2/4/7/8/9 signaling pathways in macrophages.
Topics: Animals; Anti-Inflammatory Agents; Chemokines; Female; Interleukin-6; Lipopolysaccharides; Macrophag | 2021 |